Clinical Success in Outpatient Treatment of Complicated Urinary Tract Infections with Ertapenem

SAN FRANCISCO, CA (October 4, 2013) – A retrospective database review was conducted of patients aged 18 and older receiving ertapenem therapy for UTI between July 1, 2010, and December 31, 2013. Seventy-five patients with a UTI diagnosis and available culture data were randomly selected from four participating Infectious Disease Physician Office Infusion Centers (POICs). Females accounted for 72%, 59% of patients had recurrent UTIs. Ertapenem was initiated in 55 % of patients in the POIC. E.coli was the predominant organism (75%). Overall ESBL and MDR rates in the outpatient setting were high. ESBL-producing organisms accounted for 82% and MDR was seen in 85% of organisms. Clinical success was achieved in 95% of patients (76% cured and 16% improved). Overall, adverse events occurred in 22 patients, almost all with mild to moderate reactions. The research suggests that treatment of complicated UTIs with ertapenem therapy achieved clinical success and was well tolerated. With a high success rate in drug-resistant pathogens, ertapenem appears to be safe and effective in the treatment of complicated UTIs in the POIC. To learn more, click here.

This study was presented at the 2nd annual IDWeek™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2013
IDWeek 2013 is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2013 took place October 2-6 at the Moscone Center in San Francisco, California. For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.